Vigonvita Life Sciences
Clinical trials sponsored by Vigonvita Life Sciences, explained in plain language.
-
New drug VV119 aims to tame schizophrenia symptoms
Disease control Not yet recruitingThis study tests an experimental drug called VV119 in adults with acute schizophrenia. Participants receive one of three doses of VV119, a placebo, or an active comparator (aripiprazole) for six weeks. The goal is to see if VV119 reduces symptoms like hallucinations and delusions…
Phase: PHASE2 • Sponsor: Vigonvita Life Sciences • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a new pill help men last longer? a trial puts VV913 to the test
Symptom relief Not yet recruitingThis trial tests whether an experimental drug called VV913 can help men with premature ejaculation last longer during intercourse. About 500 men aged 18 to 55 with diagnosed premature ejaculation will take either VV913 (at one of three doses) or a placebo pill before sex. Researc…
Phase: PHASE2 • Sponsor: Vigonvita Life Sciences • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
First human study of VV261: a new pill under the microscope
Knowledge-focused Not yet recruitingThis early-stage trial tests the safety and how the body handles VV261 tablets in healthy Chinese adults aged 18 to 45. Participants receive either VV261 or a placebo multiple times daily. Researchers measure drug levels in the blood and monitor for any side effects. The goal is …
Phase: PHASE1 • Sponsor: Vigonvita Life Sciences • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC